Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HD21 for advanced stages: BrECADD vs escalated BEACOPP in first-line advanced Hodgkin lymphoma
2014-005130-55Phase 3Active
- Sponsor
- University of Cologne
- Start
- Jan 2016
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of brentuximab vedotin in classical Hodgkin lymphoma (cHL) (2 arms), sponsored by University of Cologne. Primary endpoint: Non-inferior efficacy of BrECADD vs escalated BEACOPP. Started Jan 2016; status: active.
02
Drugs
brentuximab vedotin
03
Conditions
classical Hodgkin lymphoma (cHL)
Beyond the preview
Go deeper on 2014-005130-55.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-005130-55.